Kephera Diagnostics Revenue and Competitors
Estimated Revenue & Valuation
- Kephera Diagnostics's estimated annual revenue is currently $2M per year.
- Kephera Diagnostics's estimated revenue per employee is $155,000
Employee Data
- Kephera Diagnostics has 13 Employees.
- Kephera Diagnostics grew their employee count by 8% last year.
Kephera Diagnostics's People
Name | Title | Email/Phone |
---|
Kephera Diagnostics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Kephera Diagnostics?
Kephera Diagnostics, LLC is a start-up focused on development of point-of-care assays for a variety of disease conditions. Areas of focus include emerging pathogens that are of high global public health significance. We work with research partners in academic and government laboratories in the U.S. and internationally to translate basic science into effective diagnostic products that address under-served medical needs. To meet this challenge, we are developing new and innovative assay technologies. Kephera has been funded under an NIH grant to develop a test for Zika virus infection that will enable diagnosis of exposed individuals, including pregnant women and others at risk of serious complications. Tests for other vector-borne viral and parasitic infections are also in the pipeline.
keywords:N/AN/A
Total Funding
13
Number of Employees
$2M
Revenue (est)
8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.2M | 14 | 0% | N/A |
#2 | $0.9M | 14 | -48% | N/A |
#3 | $1.2M | 14 | 0% | N/A |
#4 | $2.3M | 15 | -6% | N/A |
#5 | $0.5M | 15 | -29% | $3.9M |